Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" Phenomenon

Sponsor

Bial - Portela C S.A. (Industry)

Overall Status

Completed

CT.gov ID

NCT03103399

Collaborator

(none)

254

Enrollment

Arms

11.8

Actual Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of this study was to investigate the effect on the "wearing-off" phenomenon of 3 different doses of nebicapone (NEB 50 mg, 100 mg and 150 mg), compared with entacapone and placebo when dministered concomitantly with existing treatment with levodopa plus a dopa decarboxylase inhibitor (DDCI: carbidopa or benserazide).

Condition or Disease	Intervention/Treatment	Phase
Parkinson Disease	Drug: Comtan® Drug: Nebicapone Drug: Levodopa/DDCI Drug: Placebo	Phase 2

Detailed Description

The study was conducted in 40 sites in Europe and South America: Argentina (6); Austria (2); Brazil (5); France (1); Hungary (4); Poland (7); Portugal (2); Romania (7); and Ukraine (6).

Multicentre study with a screening visit (Visit V1), a single-blind placebo run-in period of 1 or 2 weeks (Period 1, Visits V2 to V3), and an 8-week randomised, double-blind, activeand placebo-controlled, parallel-group (5 groups) treatment period (Period 2, Visits V3 to V7). In Hungary only: a 1-week tapering-off period was added by amendment #1HU. The dosage of nebicapone was to be tapered off stepwise during 6 days. This period was to end with a follow-up Visit V8.

Study Design

Study Type:

Interventional

Actual Enrollment :

254 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double (Participant, Investigator)

Primary Purpose:

Treatment

Official Title:

A Multicentre, Double-blind, Randomised, Active- and Placebo-controlled Trial to Investigate the Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" Phenomenon Treated With Levodopa/Carbidopa or Levodopa/Benserazide

Actual Study Start Date :

Sep 26, 2006

Actual Primary Completion Date :

Sep 21, 2007

Actual Study Completion Date :

Sep 21, 2007

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 50 mg nebicapone At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 50 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)	Drug: Nebicapone 50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose. Other Names: BIA 3-202 Drug: Levodopa/DDCI Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses. All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients. Other Names: Levodopa plus a dopa decarboxylase inhibitor (DDCI: carbidopa or benserazide) Drug: Placebo Administered orally as encapsulated tablets, which were identical in appearance to the study drugs Other Names: placebo tablets
Experimental: 100 mg nebicapone At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 100 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)	Drug: Nebicapone 50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose. Other Names: BIA 3-202 Drug: Levodopa/DDCI Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses. All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients. Other Names: Levodopa plus a dopa decarboxylase inhibitor (DDCI: carbidopa or benserazide) Drug: Placebo Administered orally as encapsulated tablets, which were identical in appearance to the study drugs Other Names: placebo tablets
Experimental: 150 mg nebicapone At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 150 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)	Drug: Nebicapone 50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose. Other Names: BIA 3-202 Drug: Levodopa/DDCI Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses. All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients. Other Names: Levodopa plus a dopa decarboxylase inhibitor (DDCI: carbidopa or benserazide) Drug: Placebo Administered orally as encapsulated tablets, which were identical in appearance to the study drugs Other Names: placebo tablets
Active Comparator: 200 mg entacapone At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 200 mg of entacapone (Comtan®) in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)	Drug: Comtan® 200 mg entacapone were to be taken concomitantly with each levodopa/DDCI dose. Other Names: entacapone Drug: Levodopa/DDCI Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses. All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients. Other Names: Levodopa plus a dopa decarboxylase inhibitor (DDCI: carbidopa or benserazide) Drug: Placebo Administered orally as encapsulated tablets, which were identical in appearance to the study drugs Other Names: placebo tablets
Placebo Comparator: Placebo At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive study treatment matching placebo tablets in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)	Drug: Levodopa/DDCI Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses. All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients. Other Names: Levodopa plus a dopa decarboxylase inhibitor (DDCI: carbidopa or benserazide) Drug: Placebo Administered orally as encapsulated tablets, which were identical in appearance to the study drugs Other Names: placebo tablets

Outcome Measures

Primary Outcome Measures

Change from baseline in absolute "off" time (time with poor mobility or complete immobility) at Visit V7 [8 weeks]
Baseline values for all efficacy variables were the values from Visit V3, and change from baseline refers to absolute change from baseline at Visit 7 (end of the 8-week treatment period)

Secondary Outcome Measures

Proportion of "off" time responders [8 weeks]
"off" time responders are defined as patients with a reduction of at least 1 hour in absolute "off" time since baseline (Visit V3).
Proportion of "on" time responders [8 weeks]
"on" time responders are defined as patients with an increase of at least 1 hour in absolute total "on" time since baseline (Visit V3).

Eligibility Criteria

Criteria

Ages Eligible for Study:

30 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

At Visit V1 (screening), patients had to be/have:

Ability to comprehend and willingness to sign an informed consent form
Aged 30 to 80 years, inclusive
Diagnosis of idiopathic Parkinson's disease according to the Brain Bank Clinical Diagnosis Criteria of the UK Parkinson's Disease Society [Hughes et al, 1992]
Disease severity less than Stage 5 (modified Hoehn & Yahr staging) while during the "off" time
Treated with levodopa plus DDCI for at least 1 year with clear clinical improvement
Treated with 4 to 8 (inclusive) daily doses of standard levodopa plus DDCI (bedtime dose of a slow-release formulation is permitted)
Stable regimen of levodopa plus DDCI and other anti Parkinson drugs for at least 4 weeks before screening
Signs of end-of-dose "wearing-off" phenomenon (end-of-dose deterioration) with average total daily "off" time while awake of at least 1.5 hours excluding the early morning pre first dose "off" period despite optimal anti Parkinson therapy, determined subjectively and objectively (observations of the investigator) for a minimum of 2 months before screening
Ability to keep reliable diaries of motor fluctuations (alone or with family/caregiver assistance)
Patient must be amenorrhoeic for at least 1 year or surgically sterile for at least 6 months before screening. In case of women of childbearing potential, patient must be using double-barrier contraceptive method.

At Visit V2 (entry to Period 1), patients had to have the results of laboratory tests acceptable by the investigator (not clinically relevant for the well being of the patient or for the purpose of the study).

At Visit V3 (randomisation), patients had to have:

At least 80% treatment medication (levodopa/DDCI plus investigational product) compliance with the recommended dosage regimen during Period 1
Self-rating diary charts filled in in accordance with the diary chart instructions; less than 3 errors per day are allowed
Average of at least 1.5 "off" hours per day (excluding the early morning pre first dose "off" period) on the 3 day diaries, filled in on the 3 days preceding Visit V3, according to the self-rating diary charts completed during Period 1

Exclusion Criteria:

At Visit V1 (screening), patients were not to be/have:

Non-idiopathic Parkinson's disease (atypical parkinsonism, symptomatic parkinsonism, Parkinson-plus syndrome)
Dyskinesia disability score more than 3 in the Unified Parkinson's Disease Rating Scale (UPDRS) IV.A item 33
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criterion for dementia
Major depressive episode within the 6 months before screening
Treatment with entacapone, tolcapone, neuroleptics, antidepressants (except serotonin-specific reuptake inhibitors or imipraminics [desipramine, imipramine, clomipramine and amitriptyline]), monoamine oxidase inhibitors (except selegiline up to 10 mg/day in oral formulation or 1.25 mg/day in buccal absorption formulation or rasagiline up to 1 mg/day), or antiemetics (except domperidone) within the 3 months before screening
Treatment with apomorphine within the previous month before screening
Dosage change of concomitant anti Parkinson medication within 4 weeks of screening
Any investigational product within the 3 months (or within 5 half-lives, whichever is longer) before screening
A psychiatric or any medical condition that might place the patient at increased risk or interfere with assessment
A clinically relevant electrocardiogram (ECG) abnormality
A history or current evidence of heart disease, including but not limited to myocardial infarction, angina, congestive heart failure and cardiac arrhythmia
Phaeochromocytoma
Known hypersensitivity to the ingredients of products used
Unstable concomitant disease being treated with changing doses of medication
History or current evidence of any relevant disease in the context of this study, i.e. with respect to the safety of the patient or related to the study conditions, e.g. that may influence the absorption or metabolism (e.g. hepatic impairment) of the investigational drug
Any abnormality in the liver enzymes above 2 times the upper limit of the normal range